A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckTanguy Y. Seiwert, Ezra E.W. Cohen, Didier Cupissol et al.|Annals of Oncology|2014Cited by 182